MIR4637

Across TCGA pan-cancer cohorts, MIR4637 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MIR4637 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher MIR4637 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR4637 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

PAAD, READ, and BLCA are the cancer types where MIR4637 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.189	0.555	.001	60	view →
READ	OS	Tertile	IV	0.077	1.000	.014	21	view →
BLCA	DFS	Tertile	III,IV	0.189	0.453	.003	18	view →
UCS	DFS	Tertile	II,III,IV	0.140	0.455	.024	18	view →
LAML	DFS	Median	All	0.622	0.303	.003	12	view →
GBM	OS	Tertile	All	0.208	0.429	.004	9	view →
ESCA	OS	Quartile	II,III,IV	0.552	1.000	.044	6	view →
LGG	DFS	Tertile	All	0.544	0.748	.009	6	view →
THCA	DFS	Tertile	II,III,IV	0.798	0.935	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MIR4637–PAAD (OS)

Open the PAAD breakdown →